PMV Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview

Pmv Pharmaceuticals

03/08/2026 14:44

PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 39 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $4.00, about 260.4% above its last closing price of $1.11
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.40
-0.41
-0.34
Beat
17.1
Dec. 31 2026
-0.41
-0.40
-0.34
Beat
16
Sep. 30 2025
-0.40
-0.40
-0.40
Met
0.6​
Jun. 30 2025
-0.38
-0.38
-0.41
Missed
-7
​​Mar. 31 2025
-0.38
-0.37
-0.34
Beat
9.2
Dec. 31 2024
-0.39
-0.38
-0.45
Missed
-18.2​
Sep. 30 2024
-0.36
-0.35
-0.37
Missed
-5.4
Jun. 30 2024
-0.35
-0.35
-0.02
Beat
94.3
This summary was machine generated August 3 at 13:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)